胆碱能性荨麻疹临床评估工具的开发及应用进展

doi:10.35541/cjd.20220400

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (6): 563-566.doi: 10.35541/cjd.20220400

胆碱能性荨麻疹临床评估工具的开发及应用进展

陈奇权杨显杰王文稳梁高澎宋志强

陆军军医大学西南医院皮肤科，重庆 400038

收稿日期:2022-06-07 修回日期:2022-07-26 发布日期:2023-06-05
通讯作者: 宋志强 E-mail:drsongzq@hotmail.com
基金资助:
国家自然科学基金（82003359）

Development and application of clinical assessment tools for cholinergic urticaria

Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang

Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing 400038, China

Received:2022-06-07 Revised:2022-07-26 Published:2023-06-05
Contact: Song Zhiqiang E-mail:drsongzq@hotmail.com
Supported by:
National Natural Science Foundation of China（82003359）

摘要/Abstract

摘要： 【摘要】本文全面梳理目前已经开发和验证的胆碱能性荨麻疹（CholU）临床评估工具，涉及诊断、疾病状态评估、患者生活质量评估、疾病控制情况评估等多个方面，详细介绍相关工具的使用方法及其在临床上的应用情况。

关键词: 荨麻疹, 诊断, 疾病管理, 评估工具, 胆碱能性荨麻疹

Abstract: 【Abstract】 This review comprehensively summarizes clinical assessment tools which have been developed and validated for cholinergic urticaria （CholU）, involving diagnosis and severity assessment of CholU, assessment of patients′ quality of life, and assessment of disease control. The application methods and status of relevant tools in clinical practice are introduced in detail.

Key words: Urticaria, Diagnosis, Disease management, Assessment tools, Cholinergic urticaria

陈奇权杨显杰王文稳梁高澎宋志强. 胆碱能性荨麻疹临床评估工具的开发及应用进展[J]. 中华皮肤科杂志, 2023,56(6):563-566. doi:10.35541/cjd.20220400

Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang . Development and application of clinical assessment tools for cholinergic urticaria[J]. Chinese Journal of Dermatology, 2023, 56(6): 563-566.doi:10.35541/cjd.20220400

参考文献 29

［1］	Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2022,77（3）:734⁃766. doi: 10.1111/all.15090.
［2］	Park HJ, Montgomery JR, Boggs NA. Anaphylaxis after the Covid⁃19 vaccine in a patient with cholinergic urticaria［J］. Mil Med, 2021:usab138. doi: 10.1093/milmed/usab138.
［3］	Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias ⁃ The EAACI/GA2 LEN/EDF/UNEV consensus recommendations 2016 update and revision［J］. Allergy, 2016,71（6）:780⁃802. doi: 10.1111/all.12884.
［4］	Altrichter S, Salow J, Ardelean E, et al. Development of a standardized pulse⁃controlled ergometry test for diagnosing and investigating cholinergic urticaria［J］. J Dermatol Sci, 2014,75（2）:88⁃93. doi: 10.1016/j.jdermsci.2014.04.007.
［5］	Altrichter S, Wang Y, Schumacher P, et al. Acetylcholine⁃induced whealing in cholinergic urticaria ⁃ what does it tell us?［J］. J Dermatol Sci, 2021,103（1）:10⁃15. doi: 10.1016/j.jdermsci.2021. 05.001.
［6］	Fukunaga A, Washio K, Hatakeyama M, et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management［J］. Clin Auton Res, 2018,28（1）:103⁃113. doi: 10.1007/s10286⁃017⁃0418⁃6.
［7］	Altrichter S, Schumacher P, Alraboni O, et al. Sensitization against skin resident fungi is associated with atopy in cholinergic urticaria patients［J］. Clin Transl Allergy, 2020,10:18. doi: 10.1186/s13601⁃020⁃00324⁃z.
［8］	Kim JE, Jung KH, Cho HH, et al. The significance of hypersensitivity to autologous sweat and serum in cholinergic urticaria: cholinergic urticaria may have different subtypes［J］. Int J Dermatol, 2015,54（7）:771⁃777. doi: 10.1111/ijd.12549.
［9］	Kaur I, Jakhar D. Starch⁃iodine test viewed through a dermoscope［J］. J Am Acad Dermatol, 2020,83（1）:e11⁃e12. doi: 10.1016/j.jaad.2019.08.008.
［10］	Koch K, Weller K, Werner A, et al. Antihistamine updosing reduces disease activity in patients with difficult⁃to⁃treat cholinergic urticaria［J］. J Allergy Clin Immunol, 2016,138（5）:1483⁃1485.e9. doi: 10.1016/j.jaci.2016.05.026.
［11］	Ruft J, Asady A, Staubach P, et al. Development and validation of the Cholinergic Urticaria Quality⁃of⁃Life Questionnaire （CholU⁃QoL）［J］. Clin Exp Allergy, 2018,48（4）:433⁃444. doi: 10.1111/cea.13102.
［12］	Mizuno M, Fukunaga A, Washio K, et al. A visual analogue scale for itch and pain in 23 cases of cholinergic urticaria［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:e493⁃e495. doi: 10.1111/jdv.16410.
［13］	Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire （CU⁃QoL）［J］. Allergy, 2005,60（8）:1073⁃1078. doi: 10.1111/j.1398⁃9995.2005.00833.x.
［14］	Maurer M, Zuberbier T, Metz M. The classification, pathogenesis, diagnostic workup, and management of urticaria: an update［J］. Handb Exp Pharmacol, 2022,268:117⁃133. doi: 10.1007/164_2021_506.
［15］	于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷（CU⁃Q2oL）信效度验证［J］. 中华皮肤科杂志, 2020,53（12）:992⁃997. doi: 10.35541/cjd.20200091.
［16］	Zhao Z, Zhang C, Jiang Y, et al. Chinese version of the chronic urticaria quality of life questionnaire: cultural adaptation, factor analysis, assessment of reliability and validity［J］. Arch Dermatol Res, 2021［2022⁃06⁃01］. doi: 10.1007/s00403⁃021⁃02300⁃4.
［17］	Baiardini I, Braido F, Molinengo G, et al. Chronic Urticaria Patient Perspective （CUPP）: the first validated tool for assessing quality of life in clinical practice［J］. J Allergy Clin Immunol Pract, 2018,6（1）:208⁃218. doi: 10.1016/j.jaip.2017.06.023.
［18］	Finlay AY, Khan GK. Dermatology Life Quality Index （DLQI）⁃⁃a simple practical measure for routine clinical use［J］. Clin Exp Dermatol, 1994,19（3）:210⁃216. doi: 10.1111/j.1365⁃2230.1994.tb01167.x.
［19］	Ghazanfar MN, Holm JG, Thomsen SF. Omalizumab for cholinergic urticaria: 6 months prospective study and systematic review of the literature［J］. Dermatol Ther, 2020,33（6）:e14010. doi: 10.1111/dth.14010.
［20］	Maurer M, Giménez⁃Arnau A, Ensina LF, et al. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2⁃year results［J］. World Allergy Organ J, 2020,13（9）:100460. doi: 10.1016/j.waojou.2020.100460.
［21］	Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient⁃reported outcome instrument for assessing urticaria control［J］. J Allergy Clin Immunol, 2014,133（5）:1365⁃1372. doi: 10.1016/j.jaci.2013. 12.1076.
［22］	Nakatani S, Oda Y, Washio K, et al. The Urticaria Control Test and Urticaria Activity Score correlate with quality of life in adult Japanese patients with chronic spontaneous urticaria［J］. Allergol Int, 2019,68（2）:279⁃281. doi: 10.1016/j.alit.2018.11.003.
［23］	García⁃Díez I, Curto⁃Barredo L, Weller K, et al. Cross⁃cultural adaptation of the Urticaria Control Test from German to Castilian Spanish［J］. Actas Dermosifiliogr, 2015,106（9）:746⁃752. doi: 10. 1016/j.ad.2015.05.009.
［24］	Kulthanan K, Chularojanamontri L, Tuchinda P, et al. Validity, reliability and interpretability of the Thai version of the urticaria control test （UCT）［J］. Health Qual Life Outcomes, 2016,14:61. doi: 10.1186/s12955⁃016⁃0466⁃y.
［25］	Lee JH, Bae YJ, Lee SH, et al. Adaptation and validation of the Korean version of the Urticaria Control Test and its correlation with salivary cortisone［J］. Allergy Asthma Immunol Res, 2019,11（1）:55⁃67. doi: 10.4168/aair.2019.11.1.55.
［26］	Kocatürk E, Kızıltaç U, Can P, et al. Validation of the Turkish version of the Urticaria Control Test: correlation with other tools and comparison between spontaneous and inducible chronic urticaria［J］. World Allergy Organ J, 2019,12（1）:100009. doi: 10.1016/j.waojou.2018.11.007.
［27］	Khoshkhui M, Weller K, Fadaee J, et al. Evaluation of the reliability and validity of the Persian version of Urticaria Control Test （UCT）［J］. Iran J Allergy Asthma Immunol, 2021,20（4）:423⁃431.
［28］	Dortas Junior SD, Valle S, Weller K, et al. Validity, reliability, and interpretability of the Brazilian urticaria control test［J］. Allergy Asthma Proc, 2020,41（3）:e61⁃e66. doi: 10.2500/aap.2020. 41.200003.
［29］	于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证［J］. 中华皮肤科杂志, 2020,53（7）:533⁃538. doi: 10. 35541/cjd.20191190.

[1]	米淑宏余艳琴郝金奇李薇张杨贾喜梅黄毓娴孙怀玉石继海. 丘疹脓疱型玫瑰痤疮患者皮肤高频超声联合彩色多普勒血流成像的特征[J]. 中华皮肤科杂志, 2023, 56(6): 540-544.
[2]	梁云生黎展宏伍奕蓓. [开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展[J]. 中华皮肤科杂志, 2023, 56(6): 552-558.
[3]	张立明肖汀. 慢性自发性荨麻疹的自身免疫发病机制研究进展[J]. 中华皮肤科杂志, 2023, 56(6): 567-570.
[4]	杨娜丽许秋阳吴含文叶雅慧朱吉玲刘晶晶李智铭. [开放获取] 奥马珠单抗治疗慢性荨麻疹的疗效和安全性回顾性分析[J]. 中华皮肤科杂志, 2023, 56(6): 518-524.
[5]	陈奇权孔敏敏杨显杰王欢李健张名望宋志强. [开放获取] 慢性诱导性荨麻疹患者168例过敏原反应性和特应性病史的临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 496-503.
[6]	苏畅隋秀丽刘瑞玲曹毅群姜虹严彩蓉王惠平亓玉青. [开放获取] 奥马珠单抗治疗慢性自发性荨麻疹伴有其他过敏性疾病患者74例临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 512-517.
[7]	王鑫刘丽娟李邻峰. [开放获取] 我国慢性自发性荨麻疹临床特征：基于多家医院问卷调查的流行病学研究[J]. 中华皮肤科杂志, 2023, 56(6): 525-530.
[8]	李丽俏彭聪陈翔李捷. [开放获取] 奥马珠单抗治疗对抗组胺药反应不佳的慢性荨麻疹患者单中心回顾性研究[J]. 中华皮肤科杂志, 2023, 56(6): 504-511.
[9]	陈奇权杨显杰顾恒徐金华郝飞姚煦宋志强. [开放获取] 基于德尔菲法构建《中国慢性诱导性荨麻疹诊治专家共识（2023）》[J]. 中华皮肤科杂志, 2023, 56(6): 534-539.
[10]	中华医学会皮肤性病学分会免疫学组. [开放获取] 中国慢性诱导性荨麻疹诊治专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 479-488.
[11]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 慢性自发性荨麻疹达标治疗专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 489-495.
[12]	焦晴晴张晓艳季江. 慢性自发性荨麻疹活动度相关生物学指标的研究进展[J]. 中华皮肤科杂志, 2023, 56(6): 559-562.
[13]	胡清洁周敏姚煦. 坏疽性脓皮病36例临床特点分析及PARACELSUS评分与Delphi标准的比较[J]. 中华皮肤科杂志, 2023, 56(5): 410-414.
[14]	中国医师协会皮肤科医师分会性传播疾病专业委员会. 梅毒血清固定临床管理专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(5): 383-388.
[15]	贾苇雪李诚让. 中外白癜风诊疗指南及共识比较[J]. 中华皮肤科杂志, 2023, 56(5): 471-475.

胆碱能性荨麻疹临床评估工具的开发及应用进展

Development and application of clinical assessment tools for cholinergic urticaria

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

Metrics

本文评价

推荐阅读 10